Co-Founder, President, Chief Scientific Officer & Co-Chairman, Regeneron
Search every verified George Yancopoulos interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. George Yancopoulos, co-founder, president, and chief scientific officer of Regeneron, has been a prominent voice in discussions about the state of American biotechnology and the lessons learned from the COVID-19 pandemic. In a November 2025 panel, Yancopoulos stated that the U.S. biotech market share has dropped from 80-85% to below 40% as China has risen, and argued that the U.S. needs to "keep accelerating biotech innovation." He also expressed skepticism about the role of artificial intelligence in drug discovery, saying that "AI cannot come up with a new idea" and is "entirely dependent on human genius." Yancopoulos advocated for the creation of a national database including every American's health records, DNA, and proteomics, which he said would "revolutionize science and biotechnology." Yancopoulos has also reflected on the pandemic response)Skip. In a 2022 appearance, he said that while vaccines and monoclonal antibodies were powerful, "we could have done a much better job logistically and operationally in terms of saving many many more lives." He has described Regeneron's antibody cocktail as a leading treatment given to millions before vaccination, and has noted that the company designed its cocktail to be resistant to viral variants by using two antibodies that do not block each other. Yancopoulos has also spoken about Regeneron's long-term approach to innovation, stating that the company was "losing money every year" for over 20 years while developing new technologies, and that "the strongest steel is forged in the fires of hell."
“The story of revolution medicines and the discovery of Duraxon Rasib starts with a brilliant genius professor Dr. Greg Verdine and an observation that there were a couple medicines for transplant disease that had come from nature, one from a fungus, one from a microbe that work differently than all other drugs at that...”
“We harnessed that innovation out of American academia to then say together with our partners Vertex, how can we apply a stem cell therapy where we edit the cells from the patient and put it back in the patient to potentially cure them? And the results are just dramatic.”
“The first application of CRISPR was for sickle cell disease. This is a disease we've known about for over 50 years. It's one base pair change in your genome, and it's a terrible disease. People who suffer from sickle cell disease are reliant on opioids, they have constant pain, live a terrible life. We have a chance to...”
“This commitment to the earliest stages of innovation and staying on it has resulted in a rare story. We have repeatedly delivered some of the most important medicines in medical history, not just one company that comes up with one drug.”
Is America falling behind in biotech innovation? In this must-watch panel, Amol Punjabi hosts biotech titans Alexis Borisy, Sam ...
The November 15, 2018 Lasker Lessons in Leadership was given by George Yancopoulos, Founding Scientist, President, and ...
This cancer gene therapy panel discussion sponsored by the Alliance for Cancer Gene Therapy (ACGT), featured heavyweights ...
George D. Yancopoulos, president and chief scientific officer, Regeneron Pharmaceuticals.
George Yancopoulos, the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals, says the company's COVID-19 monoclonal antibody therapy can treat people already infected or those who are immunocompromised and were exposed. Subscribe to Fox Business! https://bit.ly/2D9Cdse Watch more Fox Business Video: https://video.foxbusiness.com Watch Fox Business Network Live: http://www.foxnewsgo.com/ FOX Business Network (FBN) is a financial news channel delivering real-time information across all platforms that impact both Main Street and Wall Street. Headquartered in New York…
Regeneron Uncensored: How Decades of Investing in Innovation Powered the Rapid Fight Against COVID: Tuesday, October 19, ...
WebMD's Chief Medical Officer, John Whyte, MD, speaks with George Yancopoulos, MD, PhD, President & Chief Scientific Officer, Regeneron Pharmaceuticals Inc., about the development and promise of monoclonal antibody treatment. https://www.webmd.com/coronavirus-in-...
Regeneron co-founder George Yancopoulos shares his company’s expansion plans in Tarrytown along with his deepening concerns about COVID.
Sign in to search the full transcript archive, filter by topic, and access every quote from George Yancopoulos.